Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Badoer C, Garrec C, Goossens D, Ellison G, Mills J, Dzial M, El Housni H, Berwouts S, Concolino P, Guibert-Le Guevellou V, Delnatte C, Del Favero J, Capoluongo E, Bézieau S. Badoer C, et al. Among authors: el housni h. Oncotarget. 2016 Dec 6;7(49):81357-81366. doi: 10.18632/oncotarget.12877. Oncotarget. 2016. PMID: 27793035 Free PMC article.
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.
D'Haene N, Le Mercier M, De Nève N, Blanchard O, Delaunoy M, El Housni H, Dessars B, Heimann P, Remmelink M, Demetter P, Tejpar S, Salmon I. D'Haene N, et al. Among authors: el housni h. PLoS One. 2015 Sep 14;10(9):e0138245. doi: 10.1371/journal.pone.0138245. eCollection 2015. PLoS One. 2015. PMID: 26366557 Free PMC article. Clinical Trial.
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.
Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A. Vandeputte C, et al. Among authors: el housni h. Oncotarget. 2018 Apr 3;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707145 Free PMC article.
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B. Seremet T, et al. Among authors: el housni h. Melanoma Res. 2018 Feb;28(1):65-70. doi: 10.1097/CMR.0000000000000415. Melanoma Res. 2018. PMID: 29227333
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
Heinrichs A, Dessars B, El Housni H, Pluymers W, Peeters K, Benghiat FS, Heimann P. Heinrichs A, et al. Among authors: el housni h. Leuk Res. 2018 Apr;67:27-31. doi: 10.1016/j.leukres.2018.01.018. Epub 2018 Feb 2. Leuk Res. 2018. PMID: 29425962 Clinical Trial.
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, Del Marmol V, Heimann P, Neyns B. Seremet T, et al. Among authors: el housni h. J Transl Med. 2019 Sep 5;17(1):303. doi: 10.1186/s12967-019-2051-8. J Transl Med. 2019. PMID: 31488153 Free PMC article.
36 results